Literature DB >> 11495354

Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of Huntington's disease.

A Santamaría1, F Pérez-Severiano, E Rodríguez-Martínez, P D Maldonado, J Pedraza-Chaverri, C Ríos, J Segovia.   

Abstract

We examined the activity of striatal superoxide dismutase (SOD) in two acute pharmacological models of Huntington's disease (HD), and compared it with SOD activity in the striata of mice transgenic for the HD mutation. Total SOD, and Cu/ZnSOD activities increased in young transgenic mice, but decreased in older (35 week) mice. We consider that the increased enzyme activity represents a compensatory mechanism to protect cells from free radical-induced damage, but the system becomes insufficient in older animals. Major decreases in SOD activity were also observed both after quinolinic acid and 3-nitropropionic acid intrastriatal injections. The present results indicate that in both types of HD models striatal oxidative damage occurs, and that it is associated with alterations in the cellular antioxidant system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11495354     DOI: 10.1023/a:1010911417383

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  24 in total

1.  Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.

Authors:  A Yamamoto; J J Lucas; R Hen
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

2.  Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse.

Authors:  S J Tabrizi; J Workman; P E Hart; L Mangiarini; A Mahal; G Bates; J M Cooper; A H Schapira
Journal:  Ann Neurol       Date:  2000-01       Impact factor: 10.422

3.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid.

Authors:  M F Beal; N W Kowall; D W Ellison; M F Mazurek; K J Swartz; J B Martin
Journal:  Nature       Date:  1986 May 8-14       Impact factor: 49.962

4.  Neurons containing NADPH-diaphorase are selectively resistant to quinolinate toxicity.

Authors:  J Y Koh; S Peters; D W Choi
Journal:  Science       Date:  1986-10-03       Impact factor: 47.728

5.  Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

Authors:  L Mangiarini; K Sathasivam; M Seller; B Cozens; A Harper; C Hetherington; M Lawton; Y Trottier; H Lehrach; S W Davies; G P Bates
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

6.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.

Authors:  M Chen; V O Ona; M Li; R J Ferrante; K B Fink; S Zhu; J Bian; L Guo; L A Farrell; S M Hersch; W Hobbs; J P Vonsattel; J H Cha; R M Friedlander
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

Review 7.  Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia.

Authors:  A H Schapira
Journal:  Biochim Biophys Acta       Date:  1999-02-09

8.  Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity.

Authors:  O Hansson; A Petersén; M Leist; P Nicotera; R F Castilho; P Brundin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

9.  Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA.

Authors:  P H Reddy; M Williams; V Charles; L Garrett; L Pike-Buchanan; W O Whetsell; G Miller; D A Tagle
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

10.  Ibotenic acid-induced neuronal degeneration: a morphological and neurochemical study.

Authors:  R Schwarcz; T Hökfelt; K Fuxe; G Jonsson; M Goldstein; L Terenius
Journal:  Exp Brain Res       Date:  1979-10       Impact factor: 1.972

View more
  20 in total

1.  Increased formation of reactive oxygen species, but no changes in glutathione peroxidase activity, in striata of mice transgenic for the Huntington's disease mutation.

Authors:  Francisca Pérez-Severiano; Abel Santamaría; José Pedraza-Chaverri; Omar N Medina-Campos; Camilo Ríos; José Segovia
Journal:  Neurochem Res       Date:  2004-04       Impact factor: 3.996

Review 2.  Energy deficit in Huntington disease: why it matters.

Authors:  Fanny Mochel; Ronald G Haller
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

3.  Targeting sirtuin-1 in Huntington's disease: rationale and current status.

Authors:  Wenzhen Duan
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

Review 4.  Metabolism in HD: still a relevant mechanism?

Authors:  Wenzhen Duan; Mali Jiang; Jing Jin
Journal:  Mov Disord       Date:  2014-08-13       Impact factor: 10.338

Review 5.  Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection.

Authors:  Meijuan Zhang; Chengrui An; Yanqin Gao; Rehana K Leak; Jun Chen; Feng Zhang
Journal:  Prog Neurobiol       Date:  2012-09-29       Impact factor: 11.685

6.  Downregulation of NF-kappaB signaling by mutant huntingtin proteins induces oxidative stress and cell death.

Authors:  Sami Reijonen; Jyrki P Kukkonen; Alise Hyrskyluoto; Jenny Kivinen; Minna Kairisalo; Nobuyuki Takei; Dan Lindholm; Laura Korhonen
Journal:  Cell Mol Life Sci       Date:  2010-03-17       Impact factor: 9.261

Review 7.  The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.

Authors:  Jia Yi Li; Natalija Popovic; Patrik Brundin
Journal:  NeuroRx       Date:  2005-07

8.  Novel proteomic changes in brain mitochondria provide insights into mitochondrial dysfunction in mouse models of Huntington's disease.

Authors:  Sonal Agrawal; Jonathan H Fox
Journal:  Mitochondrion       Date:  2019-03-20       Impact factor: 4.160

9.  Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects : a cross-sectional study.

Authors:  N Klepac; M Relja; R Klepac; S Hećimović; T Babić; V Trkulja
Journal:  J Neurol       Date:  2007-11-09       Impact factor: 4.849

10.  Influence of intensive multifunctional neurorehabilitation on neuronal oxidative damage in patients with Huntington's disease.

Authors:  Irene Ciancarelli; Daniela De Amicis; Caterina Di Massimo; Giorgio Sandrini; Caterina Pistarini; Antonio Carolei; Maria Giuliana Tozzi Ciancarelli
Journal:  Funct Neurol       Date:  2015 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.